Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States

INTRODUCTION: The choice of BCR-ABL1 tyrosine kinase inhibitors (TKI) for the first line of therapy (LOT) for chronic-phase chronic myeloid leukemia (CML) is tailored to disease risk and patient characteristics like comorbidities, which become more prevalent with age. However, contemporary evaluatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Shallis, Rory M., Wang, Rong, Bewersdorf, Jan P., Zeidan, Amer M., Davidoff, Amy J., Huntington, Scott F., Podoltsev, Nikolai A., Ma, Xiaomei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832334/
https://www.ncbi.nlm.nih.gov/pubmed/35154624
http://dx.doi.org/10.1177/20406207211043404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832334/
https://www.ncbi.nlm.nih.gov/pubmed/35154624
http://dx.doi.org/10.1177/20406207211043404

Ejemplares similares